Technology | Stents Peripheral | April 27, 2016

Veniti Completes First Use of Novel Venous Stent System

Peripheral deploy venous stent system allows greater accuracy in landing peripheral stents in patients suffering from post-thrombotic syndrome associated with venous outflow obstruction

April 27, 2016 — Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering from post-thrombotic syndrome (PTS) associated with venous outflow obstruction. The stent delivery system allows the physician to deploy a venous stent beginning at the peripheral end of the common femoral vein. The stent system received CE Marking on April 1, 2016.

"Frequently, in patients with extensive venous outflow obstruction causing post-thrombotic syndrome, it is necessary to extend the stents below the inguinal ligament to cover the entirety of the common femoral vein. In these cases, accurate stent placement is essential to maintain inflow to the stent system from both the profunda and femoral veins," said Stephen Black, M.D., consultant vascular surgeon, Guy's and St. Thomas' NHS Foundation Trust, London U.K., who performed the procedure. "It is encouraging to see the team at Veniti and others in industry working with physicians to develop new products like the Vici Verto Venous Stent, which address the specific needs of the physicians treating venous disease."

PTS is a complication of deep vein thrombosis, which affects more than 1.4 million people across the United States and Western Europe each year. It is estimated that 20-50 percent of the people who have had a deep vein thrombosis will develop PTS, which can have devastating, long-term consequences affecting the quality of life for the thousands of people who suffer from the condition. Symptoms include progressive leg pain and swelling, leg heaviness and skin changes. Physicians treat the obstructive component of PTS through minimally-invasive endovascular stenting procedures. The VIRTUS Trial is being performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption to evaluate the safety and efficacy of the Vici Venous Stent for the treatment of chronic iliofemoral venous outflow obstruction.

For more information:

Related Content

American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init